Tredje AP-fonden’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.5M | Sell |
59,459
-14,340
| -19% | -$6.36M | 0.13% | 155 |
|
|
2026
Q1 | $33M | Sell |
73,799
-57,928
| -44% | -$27M | 0.18% | 111 |
|
|
2025
Q4 | $59.7M | Sell |
131,727
-53,585
| -29% | -$23.1M | 0.45% | 48 |
|
|
2025
Q3 | $72.6M | Sell |
185,312
-65,290
| -26% | -$27.3M | 0.58% | 39 |
|
|
2025
Q2 | $112M | Buy |
250,602
+209,112
| +504% | +$96.4M | 0.89% | 23 |
|
|
2025
Q1 | $20.1M | Sell |
41,490
-95,962
| -70% | -$44.7M | 0.19% | 106 |
|
|
2024
Q4 | $55.4M | Buy |
137,452
+7,978
| +6% | +$3.7M | 0.5% | 49 |
|
|
2024
Q3 | $60.2M | Buy |
129,474
+37,873
| +41% | +$18.2M | 0.55% | 43 |
|
|
2024
Q2 | $42.9M | Sell |
91,601
-12,614
| -12% | -$5.48M | 0.41% | 55 |
|
|
2024
Q1 | $43.6M | Buy |
104,215
+37,000
| +55% | +$15.6M | 0.45% | 58 |
|
|
2023
Q4 | $27.3M | Buy |
67,215
+2,410
| +4% | +$890K | 0.34% | 70 |
|
|
2023
Q3 | $22.5M | Buy |
64,805
+274
| +0.4% | +$95.8K | 0.33% | 72 |
|
|
2023
Q2 | $22.7M | Buy |
64,531
+678
| +1% | +$228K | 0.32% | 76 |
|
|
2023
Q1 | $20.1M | Buy |
63,853
+1,786
| +3% | +$536K | 0.31% | 84 |
|
|
2022
Q4 | $17.9M | Buy |
62,067
+4,418
| +8% | +$1.35M | 0.31% | 82 |
|
|
2022
Q3 | $16.7M | Buy |
57,649
+28,983
| +101% | +$8.34M | 0.35% | 75 |
|
|
2022
Q2 | $8.08M | Hold |
28,666
| – | – | 0.2% | 108 |
|
|
2022
Q1 | $7.48M | Hold |
28,666
| – | – | 0.15% | 122 |
|
|
2021
Q4 | $6.29M | Hold |
28,666
| – | – | 0.12% | 148 |
|
|
2021
Q3 | $5.2M | Hold |
28,666
| – | – | 0.11% | 152 |
|
|
2021
Q2 | $5.78M | Hold |
28,666
| – | – | 0.12% | 115 |
|
|
2021
Q1 | $6.16M | Hold |
28,666
| – | – | 0.15% | 113 |
|
|
2020
Q4 | $6.78M | Hold |
28,666
| – | – | 0.17% | 103 |
|
|
2020
Q3 | $7.8M | Hold |
28,666
| – | – | 0.25% | 74 |
|
|
2020
Q2 | $8.32M | Sell |
28,666
-31,934
| -53% | -$8.66M | 0.34% | 64 |
|
|
2020
Q1 | $14.4M | Buy |
60,600
+3,485
| +6% | +$799K | 0.75% | 37 |
|
|
2019
Q4 | $12.5M | Sell |
57,115
-1,832
| -3% | -$371K | 0.63% | 36 |
|
|
2019
Q3 | $9.99M | Buy |
58,947
+196
| +0.3% | +$34.7K | 0.48% | 46 |
|
|
2019
Q2 | $10.8M | Sell |
58,751
-99
| -0.2% | -$17.3K | 0.51% | 43 |
|
|
2019
Q1 | $10.8M | Buy |
58,850
+2,360
| +4% | +$436K | 0.56% | 41 |
|
|
2018
Q4 | $9.36M | Sell |
56,490
-36,820
| -39% | -$6.38M | 0.57% | 43 |
|
|
2018
Q3 | $18M | Hold |
93,310
| – | – | 0.87% | 25 |
|
|
2018
Q2 | $15.9M | Sell |
93,310
-18,957
| -17% | -$2.94M | 0.55% | 46 |
|
|
2018
Q1 | $18.3M | Buy |
112,267
+430
| +0.4% | +$70.2K | 0.65% | 33 |
|
|
2017
Q4 | $16.8M | Buy |
111,837
+3,860
| +4% | +$572K | 0.57% | 39 |
|
|
2017
Q3 | $16.4M | Buy |
107,977
+4,038
| +4% | +$608K | 0.58% | 35 |
|
|
2017
Q2 | $13.4M | Buy |
103,939
+9,930
| +11% | +$1.2M | 0.5% | 44 |
|
|
2017
Q1 | $10.3M | Sell |
94,009
-3,857
| -4% | -$340K | 0.4% | 58 |
|
|
2016
Q4 | $7.21M | Sell |
97,866
-201
| -0.2% | -$16.4K | 0.3% | 78 |
|
|
2016
Q3 | $8.55M | Sell |
98,067
-2,900
| -3% | -$274K | 0.39% | 61 |
|
|
2016
Q2 | $8.69M | Buy |
100,967
+1,045
| +1% | +$90.3K | 0.39% | 57 |
|
|
2016
Q1 | $8.36M | Buy |
99,922
+6,654
| +7% | +$602K | 0.38% | 61 |
|
|
2015
Q4 | $11.7M | Buy |
93,268
+77,954
| +509% | +$9.41M | 0.75% | 33 |
|
|
2015
Q3 | $1.59M | Sell |
15,314
-1,684
| -10% | -$216K | 0.16% | 162 |
|
|
2015
Q2 | $2.1M | Buy |
+16,998
| New | +$2.14M | 0.17% | 155 |
|
Other funds holding VRTX
Tredje AP-fonden's VRTX Position: Q2 2026 in Review
Tredje AP-fonden reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $6.36M and leaving 59,459 shares worth $29.5M. The position accounts for 0.13% of the portfolio, ranked #155.
Tredje AP-fonden first reported a position in VRTX in Q2 2015 and has held it in 45 quarters since. The position peaked at $112M in Q2 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Tredje AP-fonden held 59,459 shares of Vertex Pharmaceuticals worth $29.5M as of Q2 2026.
- Tredje AP-fonden sold 14,340 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.36M.
- Vertex Pharmaceuticals made up 0.13% of Tredje AP-fonden's portfolio in Q2 2026, its #155 holding.
- Tredje AP-fonden first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- Tredje AP-fonden's Vertex Pharmaceuticals position peaked at $112M in Q2 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.